ProShare Advisors
VERA icon

ProShare Advisors’s Vera Therapeutics VERA Stock Holding History

ProShare Advisors’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$460K Sell
10,722
-1,433
-12% -$53.4K ﹤0.01% 1138
2026
Q1 		$489K Sell
12,155
-783
-6% -$33.7K ﹤0.01% 1080
2025
Q4 		$655K Buy
12,938
+1,864
+17% +$66.2K ﹤0.01% 994
2025
Q3 		$322K Sell
11,074
-1,861
-14% -$43K ﹤0.01% 1371
2025
Q2 		$305K Buy
12,935
+247
+2% +$5.55K ﹤0.01% 1432
2025
Q1 		$305K Sell
12,688
-2,799
-18% -$89.9K ﹤0.01% 1401
2024
Q4 		$655K Buy
15,487
+4,883
+46% +$216K ﹤0.01% 1123
2024
Q3 		$469K Buy
10,604
+1,855
+21% +$70.4K ﹤0.01% 1174
2024
Q2 		$317K Sell
8,749
-2,136
-20% -$84.7K ﹤0.01% 1250
2024
Q1 		$469K Buy
+10,885
New +$388K ﹤0.01% 1130

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ProShare Advisors's VERA Position: Q2 2026 in Review

ProShare Advisors reduced its Vera Therapeutics (VERA) stake by 12% in Q2 2026, selling an estimated $53.4K and leaving 10,722 shares worth $460K. The position accounts for ﹤0.01% of the portfolio, ranked #1138.

ProShare Advisors first reported a position in VERA in Q1 2024 and has held it in 10 quarters since. The position peaked at $655K in Q4 2025. 220 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • ProShare Advisors held 10,722 shares of Vera Therapeutics worth $460K as of Q2 2026.
  • ProShare Advisors sold 1,433 Vera Therapeutics shares in Q2 2026, an estimated $53.4K.
  • Vera Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1138 holding.
  • ProShare Advisors first reported a position in Vera Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • ProShare Advisors's Vera Therapeutics position peaked at $655K in Q4 2025.
  • 220 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.